Hyalocytes: Essential vitreous cells in vitreoretinal health and disease

Takeshi Kita, Taiji Sakamoto, Tatsuro Ishibashi

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

Original languageEnglish
Title of host publicationVitreous
Subtitle of host publicationIn Health and Disease
PublisherSpringer New York
Pages151-164
Number of pages14
ISBN (Electronic)9781493910861
ISBN (Print)9781493910854
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Health
Vitreoretinal Surgery
Vision Disorders
Ophthalmology
Genetic Therapy
Vascular Endothelial Growth Factor A
Therapeutics
Pharmacology

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kita, T., Sakamoto, T., & Ishibashi, T. (2014). Hyalocytes: Essential vitreous cells in vitreoretinal health and disease. In Vitreous: In Health and Disease (pp. 151-164). Springer New York. https://doi.org/10.1007/978-1-4939-1086-1_10

Hyalocytes : Essential vitreous cells in vitreoretinal health and disease. / Kita, Takeshi; Sakamoto, Taiji; Ishibashi, Tatsuro.

Vitreous: In Health and Disease. Springer New York, 2014. p. 151-164.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kita, T, Sakamoto, T & Ishibashi, T 2014, Hyalocytes: Essential vitreous cells in vitreoretinal health and disease. in Vitreous: In Health and Disease. Springer New York, pp. 151-164. https://doi.org/10.1007/978-1-4939-1086-1_10
Kita T, Sakamoto T, Ishibashi T. Hyalocytes: Essential vitreous cells in vitreoretinal health and disease. In Vitreous: In Health and Disease. Springer New York. 2014. p. 151-164 https://doi.org/10.1007/978-1-4939-1086-1_10
Kita, Takeshi ; Sakamoto, Taiji ; Ishibashi, Tatsuro. / Hyalocytes : Essential vitreous cells in vitreoretinal health and disease. Vitreous: In Health and Disease. Springer New York, 2014. pp. 151-164
@inbook{9d9bb79fe1d64e419ddb5dba9d7c2b7f,
title = "Hyalocytes: Essential vitreous cells in vitreoretinal health and disease",
abstract = "Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.",
author = "Takeshi Kita and Taiji Sakamoto and Tatsuro Ishibashi",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1086-1_10",
language = "English",
isbn = "9781493910854",
pages = "151--164",
booktitle = "Vitreous",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Hyalocytes

T2 - Essential vitreous cells in vitreoretinal health and disease

AU - Kita, Takeshi

AU - Sakamoto, Taiji

AU - Ishibashi, Tatsuro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

AB - Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

UR - http://www.scopus.com/inward/record.url?scp=84956824766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956824766&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1086-1_10

DO - 10.1007/978-1-4939-1086-1_10

M3 - Chapter

AN - SCOPUS:84956824766

SN - 9781493910854

SP - 151

EP - 164

BT - Vitreous

PB - Springer New York

ER -